IVF Treatment Planning in 2026: How Medication Price-Fixing Lawsuits and IVF Tourism to Greece Should Shape Your Next $28K–$65K Cycle Decision
You've probably seen the headlines: the administration promised to make IVF "more affordable." Meanwhile your clinic just quoted you $16,500, and you already know from your last cycle that the real number lands closer to $30K once meds, monitoring, and the frozen embryo transfer show up on the bill. So when you read that Americans are flying to Greece for a $7,000 IVF cycle, the math starts to feel less like a novelty story and more like a real question: should I be planning my next cycle here, or somewhere else entirely?
I built a spreadsheet during my own three cycles because nobody could give me a straight answer to that question. Here's what I've learned about actually planning a cycle — timeline, protocol, medication sourcing, and location — using your own numbers instead of a clinic's opening quote.
Why "more affordable IVF" hasn't shown up in your quote yet
Per KFF Health News' reporting on IVF tourism, despite political promises to lower fertility treatment costs, a single U.S. IVF cycle still runs into the tens of thousands of dollars — which is exactly why a growing number of patients are booking flights to Greece and other parts of Europe for treatment that costs a fraction of the domestic price. That gap isn't closing on its own, and if you're planning your next cycle around the assumption that costs are coming down, you're planning around a policy promise, not a receipt.
This matters for treatment planning specifically because the decision in front of you right now isn't "IVF or not." It's: which protocol, which clinic, and possibly which country, gets me to a live birth for the total dollar amount and timeline I can actually sustain.
The first two weeks decide more than you think
Healthcare Dive's coverage of specialty pharmacy onboarding — "The First 14 Days" — makes a point that translates directly to fertility care, even though it wasn't written about IVF: the earliest phase of any complex treatment (baseline labs, protocol selection, medication ordering, care coordination) determines whether the rest of the journey goes smoothly or falls apart. Specialty pharmacy programs exist because patients who get lost in the first two weeks — confused about dosing, waiting on prior authorization, unsure which pharmacy fills what — are far more likely to drop off treatment or have it delayed.
IVF has the exact same failure point, just less formalized. Your AMH and antral follicle count (AFC) — the two main markers of ovarian reserve — get pulled in week one. Your protocol (antagonist, long agonist, mini-IVF, etc.) gets chosen based on those numbers. Your medication order goes in immediately after. If any of that gets mishandled — wrong protocol for your reserve, medication ordered from an out-of-network specialty pharmacy, monitoring appointments not scheduled around your work calendar — you're not just losing money, you're losing a cycle to cancellation or a poorly-timed retrieval.
Before you commit to a next cycle, ask your clinic directly: who coordinates your first 14 days, how quickly medications get ordered once a protocol is chosen, and what your nurse-to-patient ratio looks like during monitoring. Clinics with dedicated care coordinators tend to have lower unplanned cancellation rates — which matters because every cancelled cycle is money and time you don't get back.
Your medication bill might be inflated by more than clinical necessity
Here's a detail that doesn't usually make it into fertility content: Florida's attorney general recently sued pharmacy benefit managers Express Scripts and Prime Therapeutics over alleged price-fixing on specialty drug pricing. IVF medications — Gonal-F, Follistim, Menopur, Cetrotide, Ganirelix — are all specialty-tier drugs that run through exactly this kind of PBM infrastructure. If PBMs are colluding on pricing for one class of specialty drugs, there's no reason to assume fertility medications are immune from the same distortions.
What this means practically: the $6,000–$9,000 medication estimate your clinic hands you is not a fixed market price. It's a price shaped by which PBM your insurance uses, which specialty pharmacy is in-network, and pricing arrangements you have zero visibility into. Two patients on an identical antagonist protocol can pay meaningfully different amounts depending entirely on pharmacy routing — sometimes a $1,500–$3,000 spread for the same drugs at the same doses. We've written more on how pharmacy discount coupons and PBM consolidation push a $15K quote toward $35K out of pocket, and the price-fixing allegations only reinforce the point: get medication quotes from at least two specialty pharmacies before you assume the number your clinic hands you is the floor.
The real cost comparison: US clinic tiers vs. Greece
Let's put real numbers next to each other, because "$7K in Greece" and "$16.5K quoted domestically" are not comparable figures on their own — you have to build out the total cost for each path the way you would for any two U.S. clinics.
| Cost component | Budget US clinic | Premium US clinic | Greece cycle |
|---|---|---|---|
| Clinic quote (retrieval + transfer) | $15,000 | $22,000 | $7,000 |
| Medications | $7,000 | $7,500 | $2,500–$3,500 |
| Monitoring/labs | $3,000 | $3,500 | Bundled |
| PGT-A (if used) | $4,500 | $5,500 | Often not offered/optional |
| Travel (2–3 trips, lodging) | — | — | $3,000–$5,000 |
| Estimated total, one cycle | ~$28,000 | ~$38,000 | ~$12,000–$16,000 |
This is exactly the kind of side-by-side math Feralyx runs automatically — so you're not manually pricing out three clinics and a plane ticket in a spreadsheet at 11pm.
The Greece number looks like an obvious win until you factor in what it doesn't give you: verified SART-style success rate reporting. U.S. clinics report cycle-by-cycle outcomes to SART, broken out by age and diagnosis, which is how you can compare apples to apples across clinics (we walk through how to actually read that data in how to read SART clinic data before committing to a $25K cycle). Greek clinics report to ESHRE under different standards, and individual clinic-level transparency varies widely. You're trading a verified $12K price for an unverified success rate — that's a real tradeoff, not a free discount.
The math that actually determines your total cost: cumulative probability
Here's the calculation most patients never run, and it's the one that matters most for treatment planning: a clinic with a higher per-cycle price can be cheaper in expectation if its success rate is high enough.
Say you're 35. A budget clinic has a 25% live birth rate per transfer for your age/diagnosis profile. A premium clinic has a 40% rate for the same profile — a gap well within the range we've documented elsewhere as a 26-30% SART success rate spread between clinics.
Expected number of cycles to live birth is roughly 1 divided by the per-cycle probability:
- Budget clinic: 1 ÷ 0.25 = 4 expected cycles → 4 × $28,000 = ~$112,000 expected total cost
- Premium clinic: 1 ÷ 0.40 = 2.5 expected cycles → 2.5 × $38,000 = ~$95,000 expected total cost
The clinic with the $10,000-higher sticker price is cheaper in expectation, because you're statistically likely to need fewer rounds to get there. This is the number that should be driving your clinic decision — not the number on the intake call.
Now look at cumulative probability across three cycles, using 1 − (1 − p)³:
- Budget clinic (p=0.25): 1 − 0.75³ = 57.8% cumulative chance of live birth after 3 cycles
- Premium clinic (p=0.40): 1 − 0.60³ = 78.4% cumulative chance after 3 cycles
That's a 20-point gap in your realistic odds of success by your third attempt — for a total spread of roughly $84,000 vs. $114,000 if you actually go the full three rounds. You can model this exact calculation for your own age, diagnosis, and the specific clinics you're considering at Feralyx, instead of estimating it off a national average that doesn't reflect your situation.
What this means for your next-cycle decision
If you're planning your next move right now, here's the sequence I'd actually walk through:
- Pull your own SART-reportable numbers — age bracket, diagnosis, AMH/AFC — and compare live birth rate per transfer across the 2-3 clinics you're actually considering, not just the one that's closest to home.
- Get a real medication quote from at least two specialty pharmacies, given what we now know about PBM pricing disputes. Don't assume your clinic's preferred pharmacy is the cheapest option.
- Run the expected-cost math, not just the sticker price. A pricier clinic with a meaningfully higher success rate can save you money and time over two or three cycles.
- If you're weighing Greece or another destination, price the full trip — travel, lodging, and the reality of 2-3 in-person visits — against a verified-success-rate US option, not against your worst domestic quote.
- Ask about your first-14-days process. Cancelled or mismanaged cycles cost you both money and a full month of your timeline.
None of this requires waiting for a policy fix that hasn't materialized. It requires treating your next cycle decision the way you'd treat any $30,000-plus purchase: with real comparison data, not a single clinic's opening number.
If you want to run this comparison with your own diagnosis, age, and the actual clinics you're weighing — including the cumulative probability math and full cost buildout — that's exactly what Feralyx is built to do. You've already done enough guessing.
Sources
- High Fertility Costs Push Americans Abroad for IVF Treatment — KFF Reproductive Health
- Florida attorney general sues PBMs Express Scripts, Prime over alleged price fixing — Healthcare Dive
- Centene taps Fannie Mae executive as CIO — Healthcare Dive
- Ally Bank Savings Interest Rate: How It Compares — NerdWallet Health
- The first 14 days: How specialty programs set patients up for success — Healthcare Dive